Coding Reference Guide Measure Year 2024 Osteoporosis Management in Women who had a Fracture (OMW)



Measure Description

The percentage of women 67-85 years of age who suffered a fracture beginning July 1, 2023 through June 30, 2024, and who had either a Bone Mineral Density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

Notes:

Fractures of finger, toe, face, and skull are not included in this measure.

Definitions

Intake Period: A 12-month (one year) window that begins on July 1, 2023 and ends on June 30, 2024. The intake period is used to capture the first fracture.

Episode Date: The date of service for an eligible encounter during the intake period with a diagnosis of fracture

- For an outpatient, observation, or Emergency Department (ED) visit, the episode date is the date of service
- For an inpatient stay, the episode date is the date of discharge
- For direct transfers, the episode date is the discharge date from the last admission

Index Episode Start Date (IESD): The earliest episode date during the intake period that meets all eligible population criteria.

BMD Test in any Setting, on the IESD or in the 180-day (six-month) Period After the IESD. If the IESD was an Inpatient Stay, a BMD Test During the Inpatient Stay	CPT: 76977, 77078, 77080, 77081,77085, 77086
	ICD10: BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1, BP4NZZ1, BP4PZZ1, BQ00ZZ1, BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BR00ZZ1, BR07ZZ1, BR09ZZ1, BR0GZZ1
	SNOMED: 22059005, 312681000, 385342005, 391057001, 391058006, 391059003, 391060008, 391061007, 391062000, 391063005, 391064004, 391065003, 391066002, 391069009, 391070005, 391071009, 391072002, 391073007, 391074001, 391076004, 391078003, 391079006, 391080009, 391081008, 391082001, 440083004, 440099005, 440100002, 449781000, 707218004, 4211000179102
Long-acting Osteoporosis Medication Therapy During the Inpatient stay, if the IESD was an Inpatient Stay	Long-acting Osteoporosis Medications HCPCS: J0897: Denosumab, 1mg, Injection J1740: Ibandronate sodium, 1mg, Injection J3489: Zoledronic Acid, 1mg, Injection
Osteoporosis Medication Therapy or a Dispensed Prescription to Treat Osteoporosis on the IESD or in the 180-day (six-month) period after the IESD	Osteoporosis Medications Bisphosphonates HCPCS: J1740: Ibandronate sodium, 1mg, Injection J3489: Zoledronic Acid, 1mg, Injection Alendronate Alendronate-cholecalciferol Risedronate Other Agents
	HCPCS: J0897: Denosumab, 1mg, Injection J3111: Romosozumab-aqqg, 1mg, Injection J3110: Teriparatide, 10mcg, Injection Abaloparatide Raloxifene

The following will exclude Members from this measure:

Members who had a BMD test during the 730 days (24 months) prior to the episode date.

Members who had a claim/encounter for osteoporosis medication therapy during the 365 days (12 months) prior to the episode date.

Members who received a dispensed prescription or had an active prescription to treat osteoporosis during the 365 days (12 months) prior to the episode date.

Members who died any time during 2024	
	HCPCS: G9473, G9474, G9475, G9476, G9477, G9478, G9479, Q5003, Q5004, Q5005, Q5006, Q5007, Q5008, Q5010, S9126, T2042, T2043, T2044, T2045, T2046
Hospice Encounter During 2024	SNOMED: 183919006, 183921001, 305336008, 305911006, 385765002
	UBREV: 0115, 0125, 0135, 0145, 0155, 0235, 0650, 0651, 0652, 0655, 0656, 0657, 0658, 0659
Hospice Intervention During 2024	CPT: 99377, 99378
	HCPCS: G0182
	SNOMED: 170935008, 170936009, 385763009
Palliative Care Assessment Any Time During the Intake Period (July 1, 2023-June 30, 2024)	SNOMED: 718890006, 718893008, 718895001, 718898004, 718899007, 718901003, 718903000, 718904006, 718957007, 718967002, 718969004, 718971004, 718973001, 718974007, 718975008, 718976009, 761865002, 761866001, 761867005, 457511000124100
Palliative Care Encounter Any Time During the Intake Period (July 1, 2023-June 30, 2024)	HCPCS: G9054, M1017
	ICD10: Z51.5
	SNOMED: 305284002, 305381007, 305686008, 305824005, 441874000, 713281006, 4901000124101

Palliative Care Intervention Any	SNOMED:
Time During the Intake Period	103735009, 105402000, 395669003, 395670002, 395694002, 395695001, 443761007, 1841000124106,
(July 1, 2023-June 30, 2024)	433181000124107
Members 67 years of age and	 Enrolled in an Institutional Special Needs Plan (I-SNP) any time between July 1, 2023-December
older as of December 31, 2024,	31, 2024
who meet either of the following	 Living long-term in an institution any time between July 1, 2023-December 31, 2024
criteria	
Members 67-80 Years of Age as of December 31, 2024 with Frailty and Advanced Illness	 At least two indications of Frailty with different dates of service between July 1, 2023-December 31, 2024 Any of the following during 2023 or 2024: At least two outpatient visits, observation visits, e-visits or virtual check-ins, nonacute inpatient encounters, or nonacute inpatient discharges with an advanced illness diagnosis. Visit type need not be the same for the two visits At least one acute inpatient encounter with an advanced illness diagnosis At least one acute inpatient discharge with an advanced illness diagnosis on the discharge claim

Tips and Best Practices to Help Improve Performance

- Utilize the monthly Gaps in Care Report (GIC) for a list of MVP Members and the services they still need
- Obtain an annual health history and include review of prescription and OTC medications, nutrition, lifestyle, exercise, fall prevention, preventive care, and medical/surgical history
- Discuss the importance of early detection and encourage preventive care
- Educate patients on primary prevention of osteoporosis
- Follow osteoporosis screening recommendations
- Submit results to your local Regional Health Information Organization (RHIO)
- Use correct diagnosis and procedure codes and submit claims and encounter data in a timely manner
- Stock patient areas and exam rooms with educational materials such as those found here:
 - o Does Osteoporosis Run in Your Family? | CDC
 - o Health & Wellness MVP Health Care